ReviewImmunologic research2001
Cytokines in posterior uveitis: an update.
Review in Immunologic research, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 17 citations in OpenAlex.
- Cytokines in PD-1 immune checkpoint inhibitor adverse events and implications for the treatment of uveitis.BMC ophthalmology · 2024Review
- Overexpression of fractalkine and its histopathological characteristics in primary pterygium.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2019Article
- miR‑320a upregulation contributes to the development of preeclampsia by inhibiting the growth and invasion of trophoblast cells by targeting interleukin 4.Molecular medicine reports · 2019Article
- Role of DAF in protecting against T-cell autoreactivity that leads to experimental autoimmune uveitis.Investigative ophthalmology & visual science · 2009Article
- Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype?Clinical medicine & research · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T helper (Th) lymphocytes differentiate into two distinct subsets--Th1 and Th2--as defined by functional abilities and cytokine profiles. The functional differences between Th subsets are explained primarily through the activities of the cytokines they secrete. Interferon-gamma (IFN-gamma) is the signature cytokine of Th1 cells, which also produce interleukin-2 (IL-2) and tumor necrosis factor-beta (TNF-beta). IL-4 is the corresponding signature cytokine of Th2 cells, which also secrete IL-5, IL-6, IL-9, and IL-13. Recently, a few transcription factors have been identified that not only control the expression of cytokines of a particular type but also repress cytokines of other types. Human Th1 and Th2 cells not only produce a different set of cytokines but also exhibit distinct functional properties and the preferential expression of some activation markers. Pathophysiologically, the two subsets have been found to be mutually antagonistic. Various Th1 and Th2 cytokines appear to play an important role in the etiopathogenesis of posterior uveitis and its animal model, experimental autoimmune uveitis (EAU). The exact contribution of these mediators to uveitis remains to be defined. Recent studies suggest that a shift from Th1- to Th2-dominated response could be of therapeutic benefit. This review evaluates various studies in which uveitopathogenic and therapeutic potentials of various Th1 and Th2 cytokines have been investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.